Author/Authors :
Zare، Fatemeh نويسنده Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics and Center of Excellence in Biomathematics, Universit , , Fattahi، Mohammad Reza نويسنده Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran Fattahi, Mohammad Reza , Sepehrimanesh، Masood نويسنده Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran , , Safarpour، Ali Reza نويسنده Colorectal Research Center, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran; ,
Abstract :
Hepatitis C virus (HCV) infection is a major blood-borne infection which imposes high economic cost on the patients. The current study aimed to evaluate the total annual cost due to chronic HCV related diseases imposed on each patient and their family in Southern Iran. Economic burden of chronic hepatitis C-related liver diseases (chronic hepatitis C, cirrhosis and hepatocellular carcinoma) were examined. The current retrospective study evaluated 200 Iranian patients for their socioeconomic status, utilization (direct and indirect costs) and treatment costs and work days lost due to illness by a structured questionnaire in 2015. Costs of hospital admissions were extracted from databases of Nemazee hospital, Shiraz, Iran. The outpatient expenditure per patient was measured through the rate of outpatient visits and average cost per visit reported by the patients; while the inpatient costs were calculated through annual rate of hospital admissions and average expenditure. Self-medication and direct non-medical costs were also reported. The human capital approach was used to measure the work loss cost. The total annual cost per patient for chronic hepatitis C, cirrhosis and hepatocellular carcinoma (HCC) based on purchasing power parity (PPP) were USD 1625.50, USD 6117.2, and USD 11047.2 in 2015, respectively. Chronic hepatitis C-related liver diseases impose a substantial economic burden on patients, families and the society. The current study provides useful information on cost of treatment and work loss for different disease states, which can be further used in cost-effectiveness evaluations.
